Literature DB >> 29992679

Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection.

Nhung T H Trinh1,2, Elodie Solé2, Mehdi Benkebil2.   

Abstract

BACKGROUND: Change-point analysis (CPA) is a powerful method to analyse pharmacovigilance data but it has never been used on the disproportionality metric.
OBJECTIVES: To optimize signal detection investigating the interest of time-series analysis in pharmacovigilance and the benefits of combining CPA with the proportional reporting ratio (PRR).
METHODS: We investigated the couple benfluorex and aortic valve incompetence (AVI) using the French National Pharmacovigilance and EudraVigilance databases: CPA was applied on monthly counts of reports and the lower bound of monthly computed PRR (PRR-). We stated a CPA hypothesis that the substance-event combination is more likely to be a signal when the 2 following criteria are fulfilled: PRR- is greater than 1 with at least 5 cases, and CPA method detects at least 2 successive change points of PRR- which made consecutively increasing segments. We tested this hypothesis by 95 test cases identified from a drug safety reference set and 2 validated signals from EudraVigilance database: CPA was applied on PRR-.
RESULTS: For benfluorex and AVI, change points detected by CPA on PRR- were more meaningful compared with monthly counts of reports: More change points detected and detected earlier. In the reference set, 14 positive controls satisfied CPA hypothesis, 6 positive controls only met first requirements, 3 negative controls only met first requirement, and 2 validated signals satisfied CPA hypothesis.
CONCLUSIONS: The combination of CPA and PRR represents a significant advantage in detecting earlier signals and reducing false-positive signals. This approach should be confirmed in further studies.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  change-point analysis; disproportionality analysis; pharmacoepidemiology; pharmacovigilance; proportional reporting ratio; signal detection

Mesh:

Substances:

Year:  2018        PMID: 29992679     DOI: 10.1002/pds.4613

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Analyzing adverse drug reaction using statistical and machine learning methods: A systematic review.

Authors:  Hae Reong Kim; MinDong Sung; Ji Ae Park; Kyeongseob Jeong; Ho Heon Kim; Suehyun Lee; Yu Rang Park
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

2.  Identifying Actionability as a Key Factor for the Adoption of 'Intelligent' Systems for Drug Safety: Lessons Learned from a User-Centred Design Approach.

Authors:  George I Gavriilidis; Vlasios K Dimitriadis; Marie-Christine Jaulent; Pantelis Natsiavas
Journal:  Drug Saf       Date:  2021-10-21       Impact factor: 5.606

3.  Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data.

Authors:  Odile Sauzet; Victoria Cornelius
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

4.  Change Point Analysis for Detecting Vaccine Safety Signals.

Authors:  Seung-Hun You; Eun Jin Jang; Myo-Song Kim; Min-Taek Lee; Ye-Jin Kang; Jae-Eun Lee; Joo-Hyeon Eom; Sun-Young Jung
Journal:  Vaccines (Basel)       Date:  2021-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.